Details of the Drug Combination

General Information of Drug Combination (ID: DC3L5GX)

Drug Combination Name

Voxelotor

Indication

Disease Entry	Status	REF
Sickle Cell Disease	Phase 1	[1]

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Voxelotor

Disease Entry	ICD 11	Status	REF
Sickle-cell disorder	3A51	Approved	[2]

Voxelotor Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Hemoglobin (HB)	TTQO71U	HBA_HUMAN	Modulator	[2]
------------------------------------------------------------------------------------

Voxelotor Interacts with 4 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[3]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Metabolism	[3]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Metabolism	[3]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Metabolism	[3]
------------------------------------------------------------------------------------

Voxelotor Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Hemoglobin subunit beta (HBB)	OT514IKQ	HBB_HUMAN	Affects Binding	[4]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05981365) Voxelotor CYP and Transporter Cocktail Interaction Study
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
4	Voxelotor for the treatment of sickle cell disease. Expert Rev Hematol. 2021 Mar;14(3):253-262. doi: 10.1080/17474086.2021.1893688. Epub 2021 Mar 4.